Market Access

Challenging traditional processes in a changing healthcare landscape

Click here

Closing the digital expectation gap in pharma

To compete in the digital world, pharma needs to catch up to other industries by creating seamless online experiences, says Takeda’s Jan Deman

Click here

The pharma world at your fingertips

Daily and weekly email newsletters from pharmaphorum – insights and analysis on the big trends shaping healthcare and the pharmaceutical industry

Click here

Rethinking value: why diverse viewpoints matter

Defining and demonstrating value is a dynamic process, as stakeholders are likely to have varying perceptions of ‘good’, says AXON’s Shanida Nataraja

Click here

How do we make patient centricity a reality?

Giving patients a seat at the table is essential as real-time patient data gains prominence. Evidation co-founder Mikki Nasch discusses how to turn patient centricity talk into action

Click here

Leveraging KOL insights to succeed in a data-driven world

New engagement strategies are needed to effectively interact with KOLs as companies look to explore more virtual spaces, says Medscape Medical Affairs’ Christina Hoffman

Click here

ICSs: improving patient and market access at a local level

Integrated Care Systems present new opportunities for collaboration with life sciences companies, says IQVIA in a recent webinar discussion

Click here

Reflections on life sciences predictions for 2022

Technological evolution in life sciences has reached a tipping point, but what does this mean for healthcare? A new whitepaper Healthware explores key predictions for the sector

Click here

The pharmaphorum podcast

Download exclusive interviews and discussions with senior pharma and biotech executives

Click here

Is it time to rethink ePrescribing in the US?

With key industry players under scrutiny from trade regulators, a new wave of ePrescribing companies have begun to emerge in the US

Click here

The importance of newborn screening in SMA

Identifying spinal muscular atrophy early on in develop is essential for an infant’s health, yet many countries do not include SMA on their national NBS panels, as Novartis’ Mike Fraser discusses

Click here

Subscribe to future editions of Deep Dive

Sign-up to receive the next issue of pharmaphorum’s digital magazine for pharma direct to your inbox

Click here

Video
Share

Your name

Your e-mail

Name receiver

E-mail address receiver

Your message

Send

Share

E-mail

Facebook

Twitter

LinkedIn

Contact

Send